DrugPatentWatch Database Preview
Adapt Company Profile
» See Plans and Pricing
What is the competitive landscape for ADAPT, and what generic alternatives to ADAPT drugs are available?
ADAPT has six approved drugs.
There are eight US patents protecting ADAPT drugs.
There are twenty-four patent family members on ADAPT drugs in fourteen countries and thirty-one supplementary protection certificates in fourteen countries.
Summary for Adapt
International Patents: | 24 |
US Patents: | 8 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 6 |
Patent Litigation for Adapt: | See patent lawsuits for Adapt |
Drugs and US Patents for Adapt
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | RX | Yes | Yes | 9,629,965 | Start Trial | Y | Start Trial | |||
Adapt | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-001 | Nov 18, 2015 | RX | Yes | Yes | 9,468,747 | Start Trial | Y | Start Trial | |||
Adapt | NARCAN | naloxone hydrochloride | INJECTABLE;INJECTION | 016636-003 | Jun 14, 1982 | DISCN | Yes | No | Start Trial | Start Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ADAPT drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
International Patents for Adapt Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3349756 | Start Trial |
Mexico | 365383 | Start Trial |
Japan | 2017508800 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Adapt Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2316456 | CA 2017 00062 | Denmark | Start Trial | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
2316456 | C201730057 | Spain | Start Trial | PRODUCT NAME: NALTREXONA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, EN PARTICULAR CLORHIDRATO DE NALTREXONA, Y BUPROPION O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE BUPROPION.; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326 |
2316456 | LUC00054 | Luxembourg | Start Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/14/988 20150330 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |